CVRX vs LFST

For growth investors, LifeStance Health Group, Inc.

(LFST) is the stronger pick with 13. 9% revenue growth year-over-year, versus 10. 4% for CVRx, Inc. (CVRX). LifeStance Health Group, Inc. (LFST) offers the better valuation at 442. 5x trailing P/E (121. 1x forward), making it the more compelling value choice. Analysts rate CVRx, Inc. (CVRX) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, LifeStance Health Group, Inc.

(LFST) delivered a total return of -59. 6%, compared to -73. 9% for CVRx, Inc. (CVRX). Over 10 years, the gap is even starker: LFST returned -59. 6% versus CVRX's -73. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), LifeStance Health Group, Inc.

(LFST) is the lower-risk stock at 1. 20β versus CVRx, Inc. 's 1. 63β — meaning CVRX is approximately 37% more volatile than LFST relative to the S&P 500. On balance sheet safety, LifeStance Health Group, Inc. (LFST) carries a lower debt/equity ratio of 13% versus 129% for CVRx, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), LifeStance Health Group, Inc.

(LFST) is pulling ahead at 13. 9% versus 10. 4% for CVRx, Inc. (CVRX). On earnings-per-share growth, the picture is similar: LifeStance Health Group, Inc. grew EPS 113. 3% year-over-year, compared to 23. 0% for CVRx, Inc.. Over a 3-year CAGR, CVRX leads at 36. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LifeStance Health Group, Inc.

(LFST) is the more profitable company, earning 0. 7% net margin versus -94. 1% for CVRx, Inc. — meaning it keeps 0. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LFST leads at 1. 8% versus -90. 5% for CVRX. At the gross margin level — before operating expenses — CVRX leads at 85. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CVRX: 57.

1% to $11. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, LifeStance Health Group, Inc.

(LFST) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 20)). CVRx, Inc. (CVRX) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LFST: -59. 6%, CVRX: -73. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.